The week in pharma: action, reaction and insight – week to March 27, 2026

29 March 2026

By Barbara Obstoj-Cardwell. Editor

Last week’s significant research news included Pfizer and French partner Valneva releasing mixed data on their much-anticipated Phase III trial of Lyme disease vaccine candidate LB6V/VLA15. Also, Insmed announced top-line Phase IIIb data for its lung disease candidate Arikayce and regulatory filing plans. Among M&A news, Gilead Sciences announced a $2 billion+ deal to acquire Ouro Medicines and its TCE inhibitor gamgertamig, while Merck & Co revealed a takeover bid for Terns Pharmaceuticals and its leukemia candidate TERN-701.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK